SEC Form 4 · accession 0001470831-26-000848
BridgeBio Pharma, Inc. · BBIO
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Neil Kumar
Officer — Chief Executive Officer · Director
Period of report
Aug 18, 2026
Accepted (ET)
Aug 20, 2026 · 4:31 pm EDT
Rule 10b5-1 plan
yes — trade under a plan
Issuer CIK
0001743881
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Common StockF2 | Aug 18, 2026 | S | 1,900 | $81.1494 | D | 276,407 | D | |
| Common StockF3 | Aug 18, 2026 | S | 17,279 | $82.2104 | D | 259,128 | D | |
| Common StockF4 | Aug 18, 2026 | S | 14,602 | $82.9922 | D | 244,526 | D | |
| Common StockF5 | Aug 18, 2026 | S | 1,199 | $83.7732 | D | 243,327 | D | |
| Common StockF6,F7 | Aug 19, 2026 | S | 8,100 | $83.8588 | D | 507,586 | I | By Kumar Haldea Family Irrevocable Trust, of which the Reporting Person is a co-trustee. |
| Common StockF8,F7 | Aug 19, 2026 | S | 1,800 | $84.6867 | D | 505,786 | I | By Kumar Haldea Family Irrevocable Trust, of which the Reporting Person is a co-trustee. |
| Common StockF7 | Aug 19, 2026 | S | 100 | $85.65 | D | 505,686 | I | By Kumar Haldea Family Irrevocable Trust, of which the Reporting Person is a co-trustee. |
| Common StockF7 | holding | — | — | — | 3,568,447 | I | By Kumar Haldea Revocable Trust, of which the Reporting Person is a co-trustee. | |
| Common StockF9 | holding | — | — | — | 750,000 | I | By NK 2026 GRAT |
Table II — derivative securities
No Table II lines on this filing.
Explanation of responses
- F1This transaction was effected pursuant to a Rule 10b5-1 sales plan adopted by the Reporting Person on May 13, 2026.
- F2Represents the weighted average sale price of the shares sold from $80.54 to $81.53 per share. The Reporting Person will provide, upon request by the Commission staff, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate price for all transactions within the range set forth in this footnote.
- F3Represents the weighted average sale price of the shares sold from $81.62 to $82.61 per share. The Reporting Person will provide, upon request by the Commission staff, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate price for all transactions within the range set forth in this footnote.
- F4Represents the weighted average sale price of the shares sold from $82.62 to $83.61 per share. The Reporting Person will provide, upon request by the Commission staff, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate price for all transactions within the range set forth in this footnote.
- F5Represents the weighted average sale price of the shares sold from $83.65 to $83.90 per share. The Reporting Person will provide, upon request by the Commission staff, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate price for all transactions within the range set forth in this footnote.
- F6Represents the weighted average sale price of the shares sold from $83.34 to $84.31 per share. The Reporting Person will provide, upon request by the Commission staff, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate price for all transactions within the range set forth in this footnote.
- F7The Reporting Person disclaims beneficial ownership of these shares except to the extent of his pecuniary interest therein, if any, and this report shall not be deemed to be an admission that such shares are beneficially owned by the Reporting Person for Section 16 or any other purpose.
- F8Represents the weighted average sale price of the shares sold from $84.35 to $85.21 per share. The Reporting Person will provide, upon request by the Commission staff, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate price for all transactions within the range set forth in this footnote.
- F9These shares are held by the NK 2026 GRAT, a grantor retained annuity trust of which the Reporting Person is the sole trustee and sole annuitant. The Reporting Person disclaims beneficial ownership of the shares held by the NK 2026 GRAT except to the extent of his pecuniary interest therein.